
GeoVax Labs GOVX
$ 1.41
-6.0%
Quarterly report 2025-Q3
added 11-13-2025
GeoVax Labs Interest Expense 2011-2026 | GOVX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense GeoVax Labs
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.29 K | 144 K | 4.5 K | 2.59 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 144 K | 1.29 K | 38 K |
Quarterly Interest Expense GeoVax Labs
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 531 | 755 | - | 134 K | 7.15 K | 1.14 K | - | 1.05 K | 1.09 K | 1.13 K | - | 625 | 625 | 208 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 134 K | 208 | 13.5 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Amarin Corporation plc
AMRN
|
7 K | $ 14.67 | -0.07 % | $ 6.09 B | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Arena Pharmaceuticals
ARNA
|
4.16 M | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
16.4 M | - | - | $ 546 M | ||
|
Cabaletta Bio
CABA
|
2 M | $ 2.82 | 1.44 % | $ 283 M | ||
|
Avid Bioservices
CDMO
|
4.34 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
9.29 M | $ 1.29 | -3.01 % | $ 329 M | ||
|
CEL-SCI Corporation
CVM
|
746 K | $ 3.47 | -1.7 % | $ 221 M | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
3.59 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
2.7 M | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
874 K | $ 1.09 | -9.17 % | $ 22.4 M | ||
|
Enochian Biosciences
ENOB
|
122 K | - | - | $ 40.5 M | ||
|
Equillium
EQ
|
-76 K | $ 2.06 | - | $ 118 M | ||
|
Esperion Therapeutics
ESPR
|
3.49 M | $ 2.85 | 3.26 % | $ 592 M | ||
|
Eton Pharmaceuticals
ETON
|
955 K | $ 23.45 | -1.64 % | $ 631 M | ||
|
China SXT Pharmaceuticals
SXTC
|
1.62 M | $ 1.32 | -5.2 % | $ 1.88 M | ||
|
CRISPR Therapeutics AG
CRSP
|
86.6 M | $ 47.55 | 0.98 % | $ 4.28 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
459 K | $ 4.45 | -1.77 % | $ 853 M | ||
|
Allakos
ALLK
|
8 K | - | - | $ 28.6 M |